CytomX Therapeutics (NASDAQ:CTMX) Announces Quarterly Earnings Results

CytomX Therapeutics (NASDAQ:CTMX) released its earnings results on Thursday. The biotechnology company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.13), Fidelity Earnings reports. The company had revenue of $10.71 million for the quarter, compared to analyst estimates of $23.58 million. CytomX Therapeutics had a negative net margin of 158.05% and a negative return on equity of 77.05%.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Shares of NASDAQ:CTMX traded down $0.20 during trading hours on Friday, hitting $5.95. 538,700 shares of the company’s stock traded hands, compared to its average volume of 437,329. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.66 and a current ratio of 4.66. The company has a market cap of $281.99 million, a price-to-earnings ratio of -2.93 and a beta of 0.64. The company’s fifty day simple moving average is $7.14 and its two-hundred day simple moving average is $9.47. CytomX Therapeutics has a 52 week low of $5.28 and a 52 week high of $19.75.

CTMX has been the topic of several research analyst reports. ValuEngine raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Nomura reissued a “buy” rating and set a $22.00 target price on shares of CytomX Therapeutics in a research note on Sunday, August 11th. Mizuho reissued a “buy” rating and set a $16.00 target price on shares of CytomX Therapeutics in a research note on Monday, August 12th. BidaskClub cut shares of CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 1st. Finally, Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. CytomX Therapeutics presently has a consensus rating of “Buy” and an average target price of $20.14.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Recommended Story: CD Ladder

Earnings History for CytomX Therapeutics (NASDAQ:CTMX)

Leave a Reply

Your email address will not be published. Required fields are marked *

*